

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

DOCKET NO. 9511-057-27 DIV



13/C
gnd
10/7/02
A.E.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Richard J. BUCALA, et al.

ART UNIT: 1644

SERIAL NO.: 09/557,823

EXAMINER: Patrick J. Nolan

FILING DATE: April 25, 2000

FOR: INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE
TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED
TOXICITY

AMENDMENT AFTER FINAL REJECTION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

This amendment is responsive to the final Office Action in the above, dated
June 24, 2002, for which the response is due September 24, 2002. Entry and consideration of the
following amendment and remarks is respectfully requested.

IN THE CLAIMS:

Please amend the claims as follows:

66. (Twice Amended) A diagnostic method for determining the amount of MIF protein
in a patient, comprising:

- (a) obtaining a bodily fluid sample from the patient; and
- (b) determining the amount of MIF in the sample using an immunoassay with an anti-
MIF antibody, wherein the immunoassay is selected from the group consisting of ELISA,
immunoprecipitation, immunohistochemistry, and Western analysis, and wherein MIF is a
human MIF polypeptide having a molecular weight approximately 12.5 kDa, and wherein the

DO NOT
ENTER
P.N.
10-23-02

Sub
D1
C1